Spyre Therapeutics, Inc. (SYRE) Stock Price & How to Invest

Spyre Therapeutics (Nasdaq: SYRE) is a clinical-stage biotechnology company building extended half-life antibodies and antibody combinations aimed at inflammatory bowel disease (IBD), including ulcerative colitis and Crohn's disease, plus rheumatic diseases. Its lead programs target the TL1A pathway (SPY002 and SPY072) and complementary mechanisms such as alpha4beta7 (SPY001) and IL-23 (SPY003), engineered for less frequent dosing (potentially quarterly or twice-yearly) than existing biologics like Entyvio. The company has no marketed products and generates no product revenue; its worth is tied to clinical progress and the large addressable IBD market.

As a pre-revenue name, Spyre trades on pipeline expectations rather than fundamentals. A positive Part A readout from the Phase 2 SKYLINE trial in ulcerative colitis, a fully enrolled SKYWAY basket trial in rheumatic diseases, and a queue of roughly six proof-of-concept readouts slated for 2026 have driven the stock sharply higher and pulled in analyst target hikes. The flip side is heavy competition in the TL1A field from far larger players and the usual clinical-trial risk, where a single disappointing data point can reset the valuation.

Spyre is pre-revenue and unprofitable, with a net loss of roughly $149 million over the trailing twelve months (as of July 2026), so the valuation rests entirely on future clinical success. Its programs are mostly early to mid-stage, and Phase 2 results do not guarantee Phase 3 or approval; a single failed readout among the six planned for 2026 could sharply cut the stock. The TL1A space is intensely competitive, with Merck's tulisokibart already reporting pivotal ulcerative colitis data and Roche, Sanofi/Teva, and others racing ahead, meaning Spyre may reach market later than established rivals. The stock is highly volatile (beta near 3), and further equity raises would dilute holders. Any clinical, regulatory, or safety setback carries outsized downside for a company with no product sales.

14 analysts publish price targets on SYRE, averaging $105.79 against a $98.33 price as of August 2026, or +7.6%. The published targets run from $88.00 to $135.00, a moderate spread, and the ratings split 16 buy, 1 hold, 0 sell. Over the last six months there have been 10 raises and 1 cut among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.

Read the full SYRE forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.

We give no verdict on Spyre Therapeutics, Inc.. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.

The case for buying. TL1A pipeline and 2026 catalyst cadence. Spyre's core value driver is its TL1A franchise (SPY002 and SPY072) plus adjacent assets, with roughly six Phase 2 proof-of-concept readouts scheduled across 2026. The most optimistic published target, $135.00, assumes this works close to its best case.

The case against. Spyre is pre-revenue and unprofitable, with a net loss of roughly $149 million over the trailing twelve months (as of July 2026), so the valuation rests entirely on future clinical success. The most pessimistic target, $88.00, is roughly what SYRE is worth if this bites instead.

Read the full bull and bear case on SYRE, including what would have to change to break either one. Walnut is not an investment adviser.

A simple financial snapshot. These are approximations and refresh quarterly; for current figures see Spyre Therapeutics, Inc.'s investor relations page or your broker.

• Product revenue (TTM): ~$0 (clinical-stage)
• Net loss (TTM): ~-$149M
• EPS (TTM): ~-$2.17
• Cash and investments: ~$780M (runway into late 2028)
• Market cap: ~$8.2B
• 52-week range: ~$14.51 to ~$102.06

Spyre has no product revenue and posts steady losses funding R&D, so traditional earnings and valuation multiples do not apply (as of July 2026). Its roughly $8.2 billion market cap reflects expectations for its TL1A and IBD pipeline, not current cash flow. Investors weigh cash runway against clinical milestones rather than profits.

Other names that sit close to SYRE: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. Worth a look if you are thinking about diversification within a thesis rather than concentration on one ticker.

There are three common ways to get SYRE exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic portfolio, so SYRE sits alongside other stocks that express the same thesis.

Walnut takes the portfolio route. Describe a thesis where SYRE fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.

Spyre is a binary, catalyst-driven clinical-stage biotech whose story hinges on 2026-2027 trial data, not current financial results.

Whether SYRE is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is SYRE a buy or a sell?, and where the stock could go from here in the SYRE stock forecast.

For income investors, whether SYRE pays a dividend and how the payout looks is covered in does SYRE pay a dividend? And to weigh SYRE against a peer, read the full side-by-side comparisons: SYRE vs SNY and SYRE vs ABBV.